Dopamine D2 receptor binding and cerebral glucose metabolism recover after D-penicillamine-therapy in Wilson's disease

J Neurol. 1994 Oct;241(10):577-84. doi: 10.1007/BF00920620.

Abstract

Regional cerebral glucose metabolism (rCMRGlc) and dopamine D2 receptor binding were measured in a 31-year-old, severely affected, untreated patient with Wilson's disease of 3 years' duration using positron emission tomography and 18F-deoxyglucose and 18F-methylspiperone ([18F]MSP), respectively. There was a severe reduction of striatal and extrastriatal rCMRGlc as well as of striatal [18F]MSP accumulation rate. After 1 year of treatment with D-penicillamine, striatal and extrastriatal rCMRGlc and striatal [18F]MSP accumulation rate reached almost normal levels. It is hypothesized that recovery of motor functions due to copper trapping therapy was associated with an increase in basal ganglia activity and a re-expression or upregulation of dopamine D2 receptors.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Basal Ganglia / metabolism
  • Brain / metabolism*
  • Brain / pathology
  • Deoxyglucose
  • Dopamine Agents
  • Fluorine Radioisotopes
  • Glucose / metabolism*
  • Hepatolenticular Degeneration / drug therapy*
  • Hepatolenticular Degeneration / metabolism
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Neurons / metabolism
  • Penicillamine / therapeutic use*
  • Receptors, Dopamine D2 / metabolism*
  • Spiperone / analogs & derivatives
  • Tomography, Emission-Computed

Substances

  • Dopamine Agents
  • Fluorine Radioisotopes
  • Receptors, Dopamine D2
  • Spiperone
  • 3-N-methylspiperone
  • Deoxyglucose
  • Penicillamine
  • Glucose